Figure 2.

Waterfall plot of best PSA response to therapy with abiraterone acetate alone. Forty patients (69.0%) achieved a ≥50% PSA reduction, of whom 29 did not receive prior chemotherapy, 39 did not receive prior enzalutamide, and 38 who did not receive prior ketoconazole, and 21 (36.2%) achieved a ≥90% reduction. Five patients (8.6%) did not experience any PSA decline. Each bar represents an individual patient. Patients marked with an * did not have radiographic evidence of metastatic disease.